Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
Pacira BioSciences, Inc., a leading company in non-opioid pain management and regenerative health solutions, has announced the appointment of four highly accomplished individuals to its Board of Directors. Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young bring diverse expertise in scientific, commercial, and financial areas, further strengthening the board’s capabilities.
The addition of these new directors reflects Pacira’s commitment to maintaining a diverse and skilled board, ensuring strong corporate governance. With their extensive experience and unique perspectives, these directors will contribute significantly to Pacira’s strategic objectives across multiple key areas.
Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics, is a renowned expert in neurology. With over 15 years of pharmaceutical experience, he has made significant contributions to research and development, medical affairs, and scientific affairs. Dr. Bigal’s expertise will be invaluable in advancing Pacira’s non-opioid pain management solutions.
Abraham Ceesay, CEO of Rapport Therapeutics, brings nearly two decades of experience in the biopharmaceutical industry. His previous roles include CEO of Tiburio Therapeutics and Chief Operating Officer at scPharmaceuticals. Mr. Ceesay’s leadership and industry knowledge will be instrumental in driving Pacira’s growth and development.
Michael Yang, with over 20 years of leadership experience in biotech, pharmaceutical, and medical device companies, has a proven track record of launching successful platforms and expanding global revenues. As the former President and CEO of ViaCyte, he played a crucial role in the company’s acquisition by Vertex. Mr. Yang’s expertise will contribute to Pacira’s commercialization efforts and product diversification.
Alethia Young, currently serving as CFO of Bicycle Therapeutics, has an extensive background in financial management and analysis. Her previous roles include CFO at Graphite Bio and senior biotech analyst positions at Cantor Fitzgerald, Credit Suisse, and Deutsche Bank. Ms. Young’s financial acumen will support Pacira’s growth strategies and enhance its financial performance.
These new appointments not only enhance Pacira’s expertise in key areas but also promote diversity in terms of race and gender. With the addition of these directors, Pacira now boasts a board of 12 experienced individuals, all with relevant industry experience.
Pacira BioSciences is committed to providing non-opioid pain management options and developing innovative interventions for debilitating conditions. The company’s three commercial-stage non-opioid treatments, EXPAREL®, ZILRETTA®, and ioveraº®, offer patients effective alternatives to opioids. Pacira’s mission to reduce overreliance on opioids aligns with the growing need for safer pain management solutions.
As Pacira continues to build upon its leadership position in non-opioid pain management, the expertise and diversity brought by these new directors will play a vital role in driving the company’s success. With a strong focus on corporate governance and a commitment to improving patient care, Pacira is poised for continued growth and innovation in the field of pain management.